D R Mould

Summary

Publications

  1. ncbi request reprint Using disease progression models as a tool to detect drug effect
    D R Mould
    Projections Research Inc, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 82:81-6. 2007
  2. doi request reprint A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma
    D R Mould
    Projections Research, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 86:190-6. 2009
  3. ncbi request reprint The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Curr Opin Drug Discov Devel 10:84-96. 2007
  4. doi request reprint Models for disease progression: new approaches and uses
    D R Mould
    Projections Research Inc, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 92:125-31. 2012
  5. pmc Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response
    D R Mould
    Projections Research, Phoenixville, PA, USA
    Br J Clin Pharmacol 64:278-91. 2007
  6. pmc Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study
    Diane R Mould
    Projections Research, Inc, Phoenixville, PA, USA
    Br J Clin Pharmacol 62:56-70. 2006
  7. doi request reprint Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
    Diane R Mould
    Projections Research Inc, Phoenixville, Pennsylvania 19460, USA
    BioDrugs 24:23-39. 2010
  8. ncbi request reprint Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Clin Pharmacol Ther 71:334-48. 2002
  9. ncbi request reprint Simulation of correlated continuous and categorical variables using a single multivariate distribution
    Stacey J Tannenbaum
    Novartis Pharmaceuticals Corp, One Health Plaza 435 1125, East Hanover, NJ 07936, USA
    J Pharmacokinet Pharmacodyn 33:773-94. 2006
  10. ncbi request reprint Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis
    Amit Roy
    Clinical Discovery, Research and Development, Bristol Myers Squibb, Princeton, NJ 08543 4000, USA
    J Clin Pharmacol 47:1408-20. 2007

Detail Information

Publications10

  1. ncbi request reprint Using disease progression models as a tool to detect drug effect
    D R Mould
    Projections Research Inc, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 82:81-6. 2007
    ..Therefore, providing answers to the more difficult question of how to use the drug in a clinical setting is essential...
  2. doi request reprint A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma
    D R Mould
    Projections Research, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 86:190-6. 2009
    ..The application of modeling was a critical step in the development of pralatrexate, yielding important suggestions for dose, scheduling, and pretreatment modifications...
  3. ncbi request reprint The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Curr Opin Drug Discov Devel 10:84-96. 2007
    ..Consequently, pharmacokinetic and pharmacodynamic modeling often plays a larger role during the development of therapeutic mAbs than for small molecules...
  4. doi request reprint Models for disease progression: new approaches and uses
    D R Mould
    Projections Research Inc, Phoenixville, Pennsylvania, USA
    Clin Pharmacol Ther 92:125-31. 2012
    ..This article provides an overview of disease-progression evaluations using these new approaches...
  5. pmc Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response
    D R Mould
    Projections Research, Phoenixville, PA, USA
    Br J Clin Pharmacol 64:278-91. 2007
    ..To characterize alemtuzumab pharmacokinetics and its exposure-response relationship with white blood cell (WBC) count in patients with B-cell chronic lymphocytic leukaemia (CLL)...
  6. pmc Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study
    Diane R Mould
    Projections Research, Inc, Phoenixville, PA, USA
    Br J Clin Pharmacol 62:56-70. 2006
    ..To examine determinants of paclitaxel disposition and the association between paclitaxel exposure and toxicity or survival in patients with advanced stage or recurrent endometrial cancer treated with doxorubicin plus paclitaxel...
  7. doi request reprint Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
    Diane R Mould
    Projections Research Inc, Phoenixville, Pennsylvania 19460, USA
    BioDrugs 24:23-39. 2010
    ..Consequently, population pharmacokinetic and pharmacodynamic model-based approaches are often implemented to evaluate mAb drug interactions...
  8. ncbi request reprint Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Clin Pharmacol Ther 71:334-48. 2002
    ..Our objective was to describe the pharmacokinetics and pharmacodynamics of topotecan in patients...
  9. ncbi request reprint Simulation of correlated continuous and categorical variables using a single multivariate distribution
    Stacey J Tannenbaum
    Novartis Pharmaceuticals Corp, One Health Plaza 435 1125, East Hanover, NJ 07936, USA
    J Pharmacokinet Pharmacodyn 33:773-94. 2006
    ..More importantly, analyzing a larger pool of data increases the precision of the covariance estimates of the covariates, thus improving the accuracy of the description of the covariate distribution in the simulated population...
  10. ncbi request reprint Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis
    Amit Roy
    Clinical Discovery, Research and Development, Bristol Myers Squibb, Princeton, NJ 08543 4000, USA
    J Clin Pharmacol 47:1408-20. 2007
    ..These modeling and simulation results indicate that the body weight-tiered abatacept therapeutic doses approximating 10 mg/kg will ensure consistent abatacept exposure and optimal IL-6 suppression...